David Lamond Increases Stake in QNCX with Recent Share Purchase
David Lamond acquired 2,700 QNCX shares at no cost, adding to insider transactions.
Key Points
- David Lamond bought 2,700 shares of QNCX on June 11, 2026, at a price of $0.00.
- QNCX shares are trading at $0.93, with peer funds like Woodline Partners and Millennium Management reducing their stakes.
- Analysts such as D. Boral Capital and JMP Securities maintain buy ratings with price targets up to $9.00.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
David Lamond recently acquired 2,700 shares of QNCX on June 11, 2026. The transaction was completed at no cost per share, indicating a strategic move by Lamond to increase his stake in the company.
Other Institutional Activity in QNCX
While Lamond is buying, some institutional investors have been adjusting their positions in QNCX. Woodline Partners LP cut its holdings by 1,421,542 shares, leaving it with 520,000 shares valued at about $527,280. Millennium Management LLC also reduced its stake, shedding 939,980 shares to hold 250,372 shares worth approximately $253,877. In contrast, Shay Capital LLC added 177,291 shares, bringing its total to the same number, valued at roughly $179,773. Meanwhile, Acadian Asset Management LLC significantly boosted its position by 157,775 shares to a total of 175,086 shares, valued at $176,000.
Quince Therapeutics, Inc. Stock Down 97.2%
QNCX shares are currently trading at $0.93. The stock has seen various institutional movements, which could impact its future trading dynamics. Investors will be watching how these insider and institutional activities influence the market perception of QNCX.
$QNCX stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Quince Therapeutics, Inc.
In addition to David Lamond, other insiders have been active in QNCX shares. On the same day, Christopher Senner also bought 2,700 shares at no cost. Previously, on May 18, 2026, Brigette Roberts, the Chief Corporate Affairs Officer, acquired a substantial 9,860,843 shares. Earlier in the year, on January 23, 2026, Brendan Hannah, serving as Chief Business Officer, Chief Operating Officer, and Chief Compliance Officer, sold 365,000 shares, while President Charles Ryan purchased 200,000 shares.
Analysts Set New Price Targets
Analysts remain optimistic about QNCX, with firms like D. Boral Capital maintaining a 'buy' rating and a price target of $5.00 as of January 29, 2026. JMP Securities also upholds a 'buy' rating, setting a higher target of $8.00. The consensus among analysts suggests a positive outlook for QNCX, with a mean target price reflecting potential growth.
Bottom Line
David Lamond's purchase of QNCX shares is a noteworthy insider transaction that could suggest confidence in the company's prospects. While the stock is currently trading at $0.93, various institutional and insider activities may influence its future trajectory. Investors and analysts alike will continue to monitor these developments closely.
Get Quince Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $QNCX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.